PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Domperidone - Nausea and vomiting (Parkinson's disease)

PAD Profile : Domperidone - Nausea and vomiting (Parkinson's disease)

Keywords :
sickness, PD
Brand Names Include :
Motilium

Traffic Light Status

Status 1 of 1.

Status :
Green
Formulations :
  • Oral suspension
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
SA
Un
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

No drugs returned.

Other Indications

Additional Documents

Type
Document
Review Date

Committee Recommendations

Date
Committee Name
Narrative
04 December 2019
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Surrey & North West Sussex Area Prescribing Committee recommends the off label use of domperidone for the treatment of nausea & vomiting  when used in Parkinson's Disease patients, as recommended within NICE Clinical Knowledge Summaries (CKS) https://cks.nice.org.uk/parkinsons-disease 

Treatment duration is restricted to a maximum of one week in all patients*.

Prescribers should ensure that the patient understands the risks and consents to using domperidone off-label noting the MHRA drug safety alert (updated December 2019)

Domperidone will be considered GREEN on the traffic light system for this indication.

*MHRA drug safety update (December 2019) https://www.gov.uk/drug-safety-update/domperidone-for-nausea-and-vomiting-lack-of-efficacy-in-children-reminder-of-contraindications-in-adults-and-adolescents

Associated BNF Codes

04. Central Nervous System
04.06.00. Drugs used in nausea and vertigo
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More